Advanced search
Publication Cover
The World Journal of Biological Psychiatry Volume 14, 2013 - Issue 5
Submit an article Journal homepage
3,287
Views
412
CrossRef citations to date
0
Altmetric
GUIDELINES

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders

Michael BauerDepartment of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Dresden, GermanyCorrespondence[email protected]
,
Andrea PfennigDepartment of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Dresden, Germany
,
Emanuel SeverusDepartment of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Dresden, Germany
,
Peter C. WhybrowDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior Los Angeles, University of California Los Angeles (UCLA), Los Angeles, CA, USA
,
Jules AngstDepartment of Psychiatry, University of Zürich, Zürich, Switzerland
,
Hans-Jürgen MöllerDepartment of Psychiatry, University of Munich, Munich, Germany
& Šon behalf of the Task Force on Unipolar Depressive Disorders show all
Pages 334-385 | Received 06 May 2013, Accepted 06 May 2013, Published online: 03 Jul 2013

References

  • Adell A. 2010. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety. IDrugs 13:900–910.
  • Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. 2005. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed?A systematic review. Eur Arch Psychiatry Clin Neurosci 255:387–400.
  • Adli M, Bauer M, Rush AJ. 2006. Algorithms and collaborative-care systems for depression: are they effective and why?A systematic review. Biol Psychiatry 59:1029–1038.
  • Adli M, Hollinde DL, Stamm T, Wiethoff K, Tsahuridu M, Kirchheiner J, et al. 2007. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol Psychiatry 62:1295–1302.
  • Adli M, Pilhatsch M, Bauer M, Koberle U, Ricken R, Janssen G, et al. 2008. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. Pharmacopsychiatry 41:252–257.
  • Adli M, Rush AJ, Moller HJ, Bauer M. 2003. Algorithms for optimizing the treatment of depression: making the right decision at the right time. Pharmacopsychiatry 36(Suppl 3): S222–229.
  • AHCPR. 1993. Depression in primary care: detection, diagnosis, and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin 5:1–20.
  • AHCPR. 1999. (Agency for Health Care Policy and Research) Evidence Report on Treatment of Depression. Newer Pharmakotherapies AHCPR pub.No.99-E014.
  • Alexopoulos G, Katz I, Reynolds C, Carpenter D, Docherty J. 2001. The expert consensus guideline series: pharmacotherapy of depressive disorders in older patients. Postgrad Med Special Report.
  • Alexopoulos GS, Raue P, Arean P. 2003. Problem-solving therapy versus supportive therapy in geriatric major depression with executive dysfunction. Am J Geriatr Psychiatry 11:46–52.
  • Allain H, Schuck S, Mauduit N. 2000. Depression in Parkinson's disease. Br Med J 320:1287–1288.
  • American College of Physicians. 2008. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149:725–733.
  • Amsterdam JD. 1991. Vol 2: refractory depression. New York: Raven Press.
  • Amsterdam JD, Berwish NJ. 1989. High dose tranylcypromine therapy for refractory depression. Pharmacopsychiatry 22: 21–25.
  • Amsterdam JD, Hornig-Rohan M. 1996. Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am 19: 371–386.
  • Amsterdam JD, Maislin G, Potter L. 1994. Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 18:243–261.
  • Andersen G, Vestergaard K, Lauritzen L. 1994. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 25:1099–1104.
  • Andersen SW, Clemow DB, Corya SA. 2005. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry 66:1468–1476.
  • Anderson IM. 2001. Meta-analytical studies on new antidepressants. Br Med Bull 57:161–178.
  • Anderson IM, Nutt DJ, Deakin JF. 2000. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 14:3–20.
  • Angst J. 1986. The course of affective disorders. Psychopathology 19(Suppl 2):47–52.
  • Angst J, Angst F, Stassen HH. 1999. Suicide risk in patients with major depressive disorder. J Clin Psychiatry 60(Suppl 2):57–62.
  • Angst J, Preisig M. 1995. Course of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweiz Arch Neurol Psychiatr 146:5–16.
  • Angst J, Stabl M. 1992. Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology (Berlin) 106(Suppl):S109–113.
  • Angst J, Stassen HH. 1994. Methodische Aspekte von Studien zur antidepressiven Wirksamkeit. Spezielle Aspekte der antidepressiven Therapie. Neuere Ergebnisse zu Moclobemid. München: MMV Medizin Verlag GmbH. p. 147–166.
  • APA. 1994. Diagnostic and statistical manual of mental disorders. 4th revision (DSM-IV). American Psychiatric Association. Washington, DC: American Psychiatric Press.
  • APA. 2000. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 157(4 Suppl):1–45.
  • APA. 2009. American Psychiatric Association: practice guidelines for the treatment of patients with panic disorder, second edition (Jan suppl). Am J Psychiatry 166:1–68.
  • APA. 2010. Practice guideline for the treatment of patients with major depressive disorder. Washington, DC: American Psychiatric Association.
  • Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. 2001. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 62:448–452.
  • Appleby L. 1992. Suicide in psychiatric patients: risk and prevention. Br J Psychiatry 161:749–758.
  • Aronson R, Offman HJ, Joffe RT, Naylor CD. 1996. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 53:842–848.
  • Artigas F, Romero L, de MC, Blier P. 1996. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19:378–383.
  • Backenstrass M, Frank A, Joest K, Hingmann S, Mundt C, Kronmuller KT. 2006. A comparative study of nonspecific depressive symptoms and minor depression regarding functional impairment and associated characteristics in primary care. Compr Psychiatry 47:35–41.
  • Baghai TC, Blier P, Baldwin DS, Bauer M, Goodwin GM, Fountoulakis KN, et al. 2011. General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 261(Suppl 3):207–245.
  • Baghai TC, Blier P, Baldwin DS, Bauer M, Goodwin GM, Fountoulakis KN, et al. 2012. Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. Eur Arch Psychiatry Clin Neurosci 262:13–22.
  • Baker CB, Tweedie R, Duval S, Woods SW. 2003. Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis. Depress Anxiety 17:1–9.
  • Bakish D. 1999. The patient with comorbid depression and anxiety: the unmet need. J Clin Psychiatry 60(Suppl 6): 20–24.
  • Baldwin RC, Anderson D, Black S, Evans S, Jones R, Wilson K, et al. 2003. Guideline for the management of late-life depression in primary care. Int J Geriatr Psychiatry 18:829–838.
  • Bandelow B, Zohar J, Kasper S, Moller HJ. 2008. How to grade categories of evidence. World J Biol Psychiatry 9:242–247.
  • Barbee JG, Conrad EJ, Jamhour NJ. 2004. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 65:975–981.
  • Barbui C, Furukawa TA, Cipriani A. 2008. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 178:296–305.
  • Bauer M, Helmchen H. 2000. General principles of the treatment of depressive and manic disorders. In: Helmchen H, Henn F, Lauter H, Sartorius N, editors. Contemporary psychiatry. Vol. 3. Heidelberg: Springer. p. 305–316.
  • Bauer M, Baur H, Berghofer A, Strohle A, Hellweg R, Muller-Oerlinghausen B, et al. 2002a. Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders. J Affect Disord 68:285–294.
  • Bauer M, Bschor T, Kunz D, Berghofer A, Strohle A, Muller-Oerlinghausen B. 2000. Double-blind, placebo- controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 157:1429–1435.
  • Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H. 2010. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 127:19–30.
  • Bauer M, Hellweg R, Graf KJ, Baumgartner A. 1998. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 18:444–455.
  • Bauer M, Pfennig A, Linden M, Smolka MN, Neu P, Adli M. 2009a. Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. J Clin Psychopharmacol 29:327–333.
  • Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. 2009b. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70:540–549.
  • Bauer M, Whybrow PC. 2001. Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry 2:59–69.
  • Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. 2002b. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5–43.
  • Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. 2002c. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 3:69–86.
  • Baumann P. 1996. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31:444–469.
  • Bech P. 2001. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol 4:337–345.
  • Bech P, Allerup P, Gram LF, Reisby N, Rosenberg R, Jacobsen O, et al. 1981. The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand 63:290–299.
  • Bech P, Cialdella P, Haugh MC, Birkett MA, Hours A, Boissel JP, et al. 2000. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 176:421–428.
  • Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ. 2012. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatr Scand 125:342–348.
  • Bech P, Rafaelsen OJ. 1980. The use of rating scales exemplified by a comparison of the Hamilton and the Bech-Rafaelsen Melancholia Scale. Acta Psychiatr Scand 62[S285]:128–132.
  • Beck AT, Rush AJ, Shaw BF, Emery G. 1979. Cognitive therapy of depression. New York: Guilford.
  • Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. 1961. An inventory for measuring depression. Arch Gen Psychiatry 4:561–571.
  • Bellack AS, Hersen M, Himmelhoch JM. 1983. A comparison of social-skills training, pharmacotherapy and psychotherapy for depression. Behav Res Ther 21:101–107.
  • Benedetti F, Serretti A, Pontiggia A, Bernasconi A, Lorenzi C, Colombo C, et al. 2005. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. NeurosciLett 376:51–55.
  • Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, et al. 2009. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 14:197–206.
  • Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. 2007. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:843–853.
  • Bertilsson L, Dahl ML, Tybring G. 1997. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl 391:14–21.
  • Binder EB, Holsboer F. 2006. Pharmacogenomics and antidepressant drugs. Ann Med 38:82–94.
  • Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, et al. 2004. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36:1319–1325.
  • Blackburn IM, Moore RG. 1997. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Br J Psychiatry 171:328–334.
  • Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R. 2010. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 167:281–288.
  • Blumenthal SJ. 1990. Youth suicide: risk factors, assessment, and treatment of adolescent and young adult suicidal patients. Psychiatr Clin North Am 13:511–556.
  • Bostwick JM, Pankratz VS. 2000. Affective disorders and suicide risk: a reexamination. Am J Psychiatry 157:1925–1932.
  • Bourgon LN, Kellner CH. 2000. Relapse of depression after ECT: a review. J ECT 16:19–31.
  • Brady KT, Clary CM. 2003. Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline. Compr Psychiatry 44:360–369.
  • Bretlau LG, Lunde M, Lindberg L, Unden M, Dissing S, Bech P. 2008. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial. Pharmacopsychiatry 41: 41–47.
  • Bromberger JT. 2004. A psychosocial understanding of depression in women: for the primary care physician. J Am Med Womens Assoc 59:198–206.
  • Brosen K. 1996. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 18:393–396.
  • Brosen K. 1998. Differences in interactions of SSRIs. Int Clin Psychopharmacol 13(Suppl 5):S45–47.
  • Brosse AL, Sheets ES, Lett HS, Blumenthal JA. 2002. Exercise and the treatment of clinical depression in adults: recent findings and future directions. Sports Med 32:741–760.
  • Bruijn JA, Moleman P, Mulder PG, van den Broek WW. 2001. Treatment of mood-congruent psychotic depression with imipramine. J Affect Disord 66:165–174.
  • Brunello N, Burrows GD, Jönsson CPB, Judd LL, Kasper S, Keller MB, et al. 1995. Critical issues in the treatment of affective disorders. Depression 3:187–198.
  • Bschor T, Baethge C. 2010. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand 121:174–179.
  • Bschor T, Berghofer A, Strohle A, Kunz D, Adli M, Muller-Oerlinghausen B, et al. 2002. How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol 22:427–430.
  • Bschor T, Canata B, Muller-Oerlinghausen B, Bauer M. 2001. Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord 64: 261–265.
  • Bschor T, Lewitzka U, Sasse J, Adli M, Koberle U, Bauer M. 2003. Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms. Pharmacopsychiatry 36(Suppl 3):S230–234.
  • Burnand Y, Andreoli A, Kolatte E, Venturini A, Rosset N. 2002. Psychodynamic psychotherapy and clomipramine in the treatment of major depression. Psychiatr Serv 53:585–590.
  • Burt VK, Suri R, Altshuler L, Stowe Z, Hendrick VC, Muntean E. 2001. The use of psychotropic medications during breast-feeding. Am J Psychiatry 158:1001–1009.
  • CANMAT. 2001. Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 46(Suppl 1):5–90S.
  • CANMAT. 2009. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.
  • Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH. 1999. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 60:45–49.
  • Chiba K, Kobayashi K. 2000. Antidepressants. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic drug interactions. Philadelphia, PA: Lippincott Williams & Wilkins, pp. 233–243.
  • Chin PC, Majdzadeh N, D’Mello SR. 2005. Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Brain Res Mol Brain Res 137:193–201.
  • Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, et al. 2005. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 4: CD004185.
  • Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. 2009. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758.
  • Cole MG, Bellavance F, Mansour A. 1999. Prognosis of depression in elderly community and primary care populations: a systematic review and meta-analysis. Am J Psychiatry 156:1182–1189.
  • Connolly KR, Thase ME. 2011. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 71:43–64.
  • Cooper C, Katona C, Lyketsos K, Blazer D, Brodaty H, Rabins P, et al. 2011. A systematic review of treatments for refractory depression in older people. Am J Psychiatry 168: 681–688.
  • Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Muhammed-Moussa S, Grupper D, et al. 2007. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 64:679–688.
  • Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. 2006. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 23:364–372.
  • Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. 2011. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. Br Med J 343:d4551.
  • Crismon ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RM, Kahn DA, et al. 1999. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 60:142–156.
  • Crossley NA, Bauer M. 2007. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 68:935–940.
  • Daban C, Martinez-Aran A, Cruz N, Vieta E. 2008. Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. J Affect Disord 110:1–15.
  • Danish University Antidepressant Group. 1986. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berlin) 90:131–138.
  • Danish University Antidepressant Group. 1993. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord 28:105–116.
  • Danish University Antidepressant Group. 1999. Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG). Clin Pharmacol Ther 66:152–165.
  • Datto CJ. 2000. Side effects of electroconvulsive therapy. Depress Anxiety 12:130–134.
  • Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, et al. 2007. Risks of congenital malformations and perinatal events among infants exposed to anti depressant medications during pregnancy. Pharmacoepidemiol Drug Saf 16:1086–1094.
  • de Jonghe F, Hendricksen M, van AG, Kool S, Peen V, Van R, et al. 2004. Psychotherapy alone and combined with pharmacotherapy in the treatment of depression. Br J Psychiatry 185:37–45.
  • DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF. 2003. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psychopharmacol 23:27–30.
  • DeRubeis RJ, Gelfand LA, Tang TZ, Simons AD. 1999. Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons. Am J Psychiatry 156:1007–1013.
  • Devanand DP. 1995. Does electroconvulsive therapy damage brain cells?Semin Neurol 15:351–357.
  • Devanand DP. 1996. Antipsychotic treatment in outpatients with dementia. Int Psychogeriatr 8(Suppl 3):355–361.
  • DGPPN. 2000. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde: Behandlungsleitlinie Affektive Erkrankungen. Darmstadt: Steinkopff.
  • DGPPN, BÄK, KBV. 2009. für die Leitliniengruppe Unipolare Depression (2009) S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression-Langfassung. Berlin, Düsseldorf: DGPPN, ÄZQ, AWMF.
  • DiMatteo MR, Lepper HS, Croghan TW. 2000. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2101–2107.
  • Dimeo F, Bauer M, Varahram I, Proest G, Halter U. 2001. Benefits from aerobic exercise in patients with major depression: a pilot study. Br J Sports Med 35:114–117.
  • Dobson KS. 1989. A meta-analysis of the efficacy of cognitive therapy for depression. J Consult Clin Psychol 57:414–419.
  • Dodd S, Horgan D, Malhi GS, Berk M. 2005. To combine or not to combine?A literature review of antidepressant combination therapy. J Affect Disord 89:1–11.
  • Dolder CR, Nelson M, Snider M. 2008. Agomelatine treatment of major depressive disorder. Ann Pharmacother 42: 1822–1831.
  • Dombrovski AY, Mulsant BH, Haskett RF, Prudic J, Begley AE, Sackeim HA. 2005. Predictors of remission after electroconvulsive therapy in unipolar major depression. J Clin Psychiatry 66:1043–1049.
  • Doree JP, Des RJ, Lew V, Gendron A, Elie R, Stip E, et al. 2007. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin 23:333–341.
  • Dudek D, Rybakowski JK, Siwek M, Pawlowski T, Lojko D, Roczen R, et al. 2010. Risk factors of treatment resistance in major depression: association with bipolarity. J Affect Disord 126:268–271.
  • Dunner DL. 2003. Treatment considerations for depression in the elderly. CNS Spectr 8(12 Suppl 3):14–19.
  • El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, et al. 2010. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 13:917–932.
  • EMA. 2011. European Medicines Agency: Guideline on clinical investigation of medicinal products in the treatment of depression. London: European Medicines Agency.
  • Enns MW, Swenson JR, McIntyre RS, Swinson RP, Kennedy SH. 2001. Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity. Can J Psychiatry 46(Suppl 1):77–90S.
  • Entsuah AR, Huang H, Thase ME. 2001. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 62:869–877.
  • Entsuah AR, Rudolph RL, Chitra R. 1995. Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: a meta-analysis. Psychopharmacol Bull 31:759–766.
  • Eyding D, Lelgemann M, Grouven U, Harter M, Kromp M, Kaiser T, et al. 2010. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. Br Med J 341:c4737.
  • Farahani A, Correll CU. 2012. Are antipsychotics or antidepressants needed for psychotic depression?A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry 73:486–496.
  • Fava GA, Rafanelli C, Grandi S, Conti S, Belluardo P. 1998. Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. Arch Gen Psychiatry 55: 816–820.
  • Fava M. 2003. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53:649–659.
  • Fava M, Kendler KS. 2000. Major depressive disorder. Neuron 28:335–341.
  • Fava M, McGrath PJ, Sheu WP. 2003a. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. J Clin Psychopharmacol 23:365–369.
  • Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, et al. 2012. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 81:87–97.
  • Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, et al. 2003b. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 26:457–94, x.
  • Fawcett J, Barkin RL. 1998. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 59:123–127.
  • FDA. 2004. FDA Statement on Recommendations of the Psychopharmacologic Drugs and Pediatric Advisory Committees.
  • FDA. 2005. US Food and Drug Administration: Antidepressant Use in Children, Adolescents, and Adults.
  • Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, et al. 2009a. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry 70:177–184.
  • Fekadu A, Wooderson SC, Markopoulou K, Cleare AJ. 2009b. The Maudsley Staging Method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms. J Clin Psychiatry 70:952–957.
  • Ferguson JM. 2001. The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 62(Suppl 3):22–34.
  • Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ. 2001. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 103:66–72.
  • Fiedorowicz JG; Swartz KL. 2004. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract 10:239–248.
  • Finfgeld DL. 2004. Serotonin syndrome and the use of SSRIs. J Psychosoc Nurs Ment Health Serv 42:16–20.
  • Fink M. 2001. Convulsive therapy: a review of the first 55 years. J Affect Disord 63:1–15.
  • Fink M, Rush AJ, Knapp R, Rasmussen K, Mueller M, Rummans TA, et al. 2007. DSM melancholic features are unreliable predictors of ECT response: a CORE publication. J ECT 23:139–146.
  • Fisch RZ. 1987. Masked depression: its interrelations with somatization, hypochondriasis and conversion. Int J Psychiatry Med 17:367–379.
  • Flint AJ. 1998. Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents. Drugs Aging 13:269–280.
  • Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. 2010. Antidepressant drug effects and depression severity: a patient-level meta-analysis. J Am Med Asoc 303:47–53.
  • Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. 1991. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851–855.
  • Frank E, Thase ME, Spanier C, Cyranowski JM, Siegel L. 2000. Psychotherapy of affective disorders. In: Helmchen H, Henn F, Lauter H, Sartorius N, editors. Contemporary psychiatry. Heidelberg: Springer. p. 348–363.
  • Franzini A, Messina G, Marras C, Savino M, Miniati M, Bugiani O, et al. 2008. Hamilton rating scale for depression-21 modifications in patients with vagal nerve stimulation for treatment of treatment-resistant depression: series report. Neuromodulation 11:267–271.
  • Freedman R, Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA, et al. 2013. The initial field trials of DSM-5: new blooms and old thorns. Am J Psychiatry 170:1–5.
  • Frieling H and Bleich S. 2006. Tranylcypromine: new perspectives on an “old” drug. Eur Arch Psychiatry Clin Neurosci 256: 268–273.
  • Furukawa TA, Streiner DL, Young LT. 2001. Antidepressant plus benzodiazepine for major depression. Cochrane Database Syst Rev 2:CD001026.
  • Gaffan EA, Tsaousis I, Kemp-Wheeler SM. 1995. Researcher allegiance and meta-analysis: the case of cognitive therapy for depression. J Consult Clin Psychol 63:966–980.
  • Gagne GG, Jr, Furman MJ, Carpenter LL, Price LH. 2000. Efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients. Am J Psychiatry 157:1960–1965.
  • Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, et al. 2008. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 23: 269–275.
  • Gartlehner G, Hansen RA, Thieda P, DeVeaugh-Geiss AM, Gaynes BN, Krebs EE, et al. 2011. Second-generation antidepressants in the pharmacologic treatment of adult depression: An Update of the 2007 Comparative Effectiveness Review. Rockville, MD; Agency for Healthcare Research and Quality (US).
  • Gaynes BN, Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Miller WC, et al. 2012. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. J Clin Psychopharmacol 32:114–119.
  • Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. 2009. What did STAR*D teach us?Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 60:1439–1445.
  • Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. 2003. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653–661.
  • Geddes JR, Freemantle N, Mason J, Eccles MP, Boyton J. 2001. Selective serotonin reuptake inhibitors (SSRIs) for depression (Cochrane Review). The Cochrane Library 3.
  • George MS, Nahas Z, Kozel FA, Goldman J, Molloy M, Oliver N. 1999. Improvement of depression following transcranial magnetic stimulation. Curr Psychiatry Rep 1: 114–124.
  • George MS, Sackeim HA, Rush AJ, Marangell LB, Nahas Z, Husain MM, et al. 2000. Vagus nerve stimulation: a new tool for brain research and therapy. Biol Psychiatry 47:287–295.
  • Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. 2012. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 69:572–579.
  • Giedke H, Klingberg S, Schwarzler F, Schweinsberg M. 2003. Direct comparison of total sleep deprivation and late partial sleep deprivation in the treatment of major depression. J Affect Disord 76:85–93.
  • Giedke H, Schwarzler F. 2002. Therapeutic use of sleep deprivation in depression. Sleep Med Rev 6:361–377.
  • Gilbert DA, Altshuler KZ, Rago WV, Shon SP, Crismon ML, Toprac MG, et al. 1998. Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry 59:345–351.
  • Gill D, Hatcher S. 2000. Antidepressants for depression in medical illness. Cochrane Database Syst Rev 4:CD001312.
  • Gloaguen V, Cottraux J, Cucherat M, Blackburn IM. 1998. A meta-analysis of the effects of cognitive therapy in depressed patients. J Affect Disord 49:59–72.
  • Gould TD, Chen G, Manji HK. 2004. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 29:32–38.
  • Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. 2003. The economic burden of depression in the United States: how did it change between 1990 and 2000?J Clin Psychiatry 64:1465–1475.
  • Greenhalgh J, Knight C, Hind D, Beverley C, Walters S. 2005. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess 9:1–iv.
  • Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. 2009. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 10:85–116.
  • Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. 2010. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 11:81–109.
  • Guscott R, Grof P. 1991. The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry 148: 695–704.
  • Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62.
  • Hautzinger M, Welz S. 2004. [Cognitive behavioral therapy for depressed older outpatients–a controlled, randomized trial]. Z Gerontol Geriatr 37:427–435.
  • Hawton K, Bergen H, Simkin S, Cooper J, Waters K, Gunnell D, et al. 2010. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry 196: 354–358.
  • Hegerl U, Allgaier AK, Henkel V, Mergl R. 2012. Can effects of antidepressants in patients with mild depression be considered as clinically significant?J Affect Disord 138:183–191.
  • Hendrick V, Fukuchi A, Altshuler L, Widawski M, Wertheimer A, Brunhuber MV. 2001. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 179:163–166.
  • Henkel V, Seemuller F, Obermeier M, Adli M, Bauer M, Mundt C, et al. 2009. Does early improvement triggered by antidepressants predict response/remission?Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 115:439–449.
  • Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S, et al. 2009. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients – findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 43:215–229.
  • Hickie IB, Rogers NL. 2011. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 378:621–631.
  • Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. 2011. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44:195–235.
  • Hiemke C, Hartter S. 2000. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85:11–28.
  • Hirschfeld RM. 2001. Clinical importance of long-term antidepressant treatment. Br J Psychiatry Suppl 42:S4–8.
  • Hirschfeld RM, Vornik LA. 2004. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. J Clin Psychiatry 65(Suppl 4):46–52.
  • Hoffbrand S, Howard L, Crawley H. 2001. Antidepressant treatment for post-natal depression (Cochrane Review). The Cochrane Library 3.
  • Hollon SD, DeRubeis RJ, Evans MD, Wiemer MJ, Garvey MJ, Grove WM, et al. 1992. Cognitive therapy and pharmacotherapy for depression. Singly and in combination. Arch Gen Psychiatry 49:774–781.
  • Hotopf M, Hardy R, Lewis G. 1997. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 170:120–127.
  • Howland R, Thase ME. 1999. What to do with SSRI nonresonders?J Psych Pract 5:216–223.
  • Husain MM, McClintock SM, Rush AJ, Knapp RG, Fink M, Rummans TA, et al. 2008. The efficacy of acute electroconvulsive therapy in atypical depression. J Clin Psychiatry 69:406–411.
  • Husain MM, Rush AJ, Fink M, Knapp R, Petrides G, Rummans T, et al. 2004. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry 65:485–491.
  • ICSI. 2011. Institute for Clinical Systems Improvement: Major Depression in Adults in Primary Care. Available from: https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_behavioral_health_guidelines/depression/ [last accessed 11 June 2013].
  • Iosifescu DV, Bankier B, Fava M. 2004. Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. Curr Psychiatry Rep 6:193–201.
  • Izzo AA. 2004. Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 42:139–148.
  • Jakobsen JC, Hansen JL, Simonsen S, Simonsen E, Gluud C. 2012. Effects of cognitive therapy versus interpersonal psychotherapy in patients with major depressive disorder: a systematic review of randomized clinical trials with meta-analyses and trial sequential analyses. Psychol Med 42:1343–1357.
  • Jarrett RB, Rush AJ. 1994. Short-term psychotherapy of depressive disorders: current status and future directions. Psychiatry 57:115–132.
  • Jick H, Kaye JA, Jick SS. 2004. Antidepressants and the risk of suicidal behaviors. J Am Med Asoc 292:338–343.
  • Jindal RD, Thase ME. 2003. Integrating psychotherapy and pharmacotherapy to improve outcomes among patients with mood disorders. Psychiatr Serv 54:1484–1490.
  • Joffe RT, Singer W, Levitt AJ, MacDonald C. 1993. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 50:387–393.
  • Kallen B. 2004. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 158:312–316.
  • Karlsson I, Godderis J, Augusto De Mendonca LC, Nygaard H, Simanyi M, Taal M, et al. 2000. A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. Int J Geriatr Psychiatry 15:295–305.
  • Kasper S, Wehr TA, Bartko JJ, Gaist PA, Rosenthal NE. 1989. Epidemiological findings of seasonal changes in mood and behavior. A telephone survey of Montgomery County, Maryland. Arch Gen Psychiatry 46:823–833.
  • Katona C. 2000. Managing depression and anxiety in the elderly patient. Eur Neuropsychopharmacol 10(Suppl 4):S427–432.
  • Katona C, Hansen T, Olsen CK. 2012. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 27:215–223.
  • Katona CL. 1994. Approaches to the management of depression in old age. Gerontology 40(Suppl 1):5–9.
  • Katona CL, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DR, Lock T, et al. 1995. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 166:80–86.
  • Katona CL, Hunter BN, Bray J. 1998. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 13:100–108.
  • Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, et al. 2004. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 29:566–579.
  • Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, et al. 2009. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 43:205–214.
  • Keller MB, Lavori PW, Rice J, Coryell W, Hirschfeld RM. 1986. The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up. Am J Psychiatry 143:24–28.
  • Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, Peveler R, et al. 2009. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technol Assess 13:iii–xi, 1.
  • Kennedy N, Paykel ES. 2004. Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord 80:135–144.
  • Kennedy SH, Lam RW, Cohen NL, Ravindran AV. 2001. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 46(Suppl 1):38–58S.
  • Kent JM. 2000. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 355:911–918.
  • Kim HL, Streltzer J, Goebert D. 1999. St. John's wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis 187:532–538.
  • Kirchheiner J, Lorch R, Lebedeva E, Seeringer A, Roots I, Sasse J, et al. 2008. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 9:841–846.
  • Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al. 2004. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442–473.
  • Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. 2008. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5:e45.
  • Klerman GL, Weissman MM. 1992. The course, morbidity, and costs of depression. Arch Gen Psychiatry 49:831–834.
  • Klerman GL, Weissman MM, Rounsaville BJ, Chevron ES. 1984. Interpersonal psychotherapy of depression. New York: Basic Books.
  • Knubben K, Reischies FM, Adli M, Schlattmann P, Bauer M, Dimeo F. 2007. A randomised, controlled study on the effects of a short-term endurance training programme in patients with major depression. Br J Sports Med 41:29–33.
  • Kok RM, Heeren TJ, Nolen WA. 2011. Continuing treatment of depression in the elderly: a systematic review and meta-analysis of double-blinded randomized controlled trials with antidepressants. Am J Geriatr Psychiatry 19:249–255.
  • Kok RM, Vink D, Heeren TJ, Nolen WA. 2007. Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial. J Clin Psychiatry 68:1177–1185.
  • Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. 2010. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 12: CD008121.
  • Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. 2007. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 164(7 Suppl): 5–53.
  • Koren G, Matsui D, Einarson A, Knoppert D, Steiner M. 2005. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?CMAJ. 172: 1457–1459.
  • Kuhs H, Farber D, Borgstadt S, Mrosek S, Tolle R. 1996. Amitriptyline in combination with repeated late sleep deprivation versus amitriptyline alone in major depression. A randomised study. J Affect Disord 37:31–41.
  • Kuhs H, Tolle R. 1991. Sleep deprivation therapy. Biol Psychiatry 29:1129–1148.
  • Kunzel HE, Ackl N, Hatzinger M, Held K, Holsboer-Trachsler E, Ising M, et al. 2009. Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol–a double-blind multicenter trial. J Psychiatr Res 43:702–710.
  • Kupfer DJ. 1993. Management of recurrent depression. J Clin Psychiatry 54(Suppl):29–33.
  • Lam RW, Hossie H, Solomons K, Yatham LN. 2004. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry 65:337–340.
  • Lam RW, Levitt AJ. 1999. Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder. Vancouver, BC, Canada: Clinical & Academic Publishing.
  • Landen M, Bjorling G, Agren H, Fahlen T. 1998. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 59:664–668.
  • Lauritzen L, Odgaard K, Clemmesen L, Lunde M, Ohrstrom J, Black C, et al. 1996. Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. Acta Psychiatr Scand 94:241–251.
  • Lawlor DA, Hopker SW. 2001. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. Br Med J 322:763–767.
  • Leucht S, Hierl S, Kissling W, Dold M, Davis JM. 2012. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 200: 97–106.
  • Levitt AJ, Lam RW, Levitan R. 2002. A comparison of open treatment of seasonal major and minor depression with light therapy. J Affect Disord 71:243–248.
  • Lewinsohn PM, Clarke G. 1984. Group treatment of depressed individuals. The coping with depression course. Adv Behav Res Ther 10:99–114.
  • Linde K, Berner MM, Kriston L. 2008. St John's wort for major depression. Cochrane Database Syst Rev 4:CD000448.
  • Linde K, Mulrow CD. 2001. St. John's wort for depression (Cochrane Review). The Cochrane Library 1.
  • Linde K, Mulrow CD, Berner M, Egger M. 2005. St John's wort for depression. Cochrane Database Syst Rev 2:CD000448.
  • Lipsey JR, Robinson RG. 1984. Nortriptyline for post-stroke depression. Lancet 1:803.
  • Lojko D, Rybakowski JK. 2007. L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. J Affect Disord 103:253–256.
  • Loo CK, McFarquhar TF, Mitchell PB. 2008. A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression. Int J Neuropsychopharmacol 11:131–147.
  • Lopes RF, Fuzikawa C, Riera R, Ramos MG, Hara C. 2013. Antidepressant combination for major depression in incomplete responders-a systematic review. J Affect Disord 144:1–6.
  • Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. 2006. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367: 1747–1757.
  • Lotufo-Neto F, Trivedi M, Thase ME. 1999. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 20:226–247.
  • Lovlie R, Daly AK, Matre GE, Molven A, Steen VM. 2001. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?Pharmacogenetics 11:45–55.
  • Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J. 2000. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 101:354–359.
  • Lyketsos CG, Sheppard JM, Steele CD, Kopunek S, Steinberg M, Baker AS, et al. 2000. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry 157: 1686–1689.
  • Mace S, Taylor D. 2000. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. Expert Opin Pharmacother 1:917–933.
  • Maes M, Vandoolaeghe E, Desnyder R. 1996. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 41:201–210.
  • Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, et al. 2007. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 147:593–602.
  • Malhi GS, Adams D, Porter R, Wignall A, Lampe L, O’Connor N, et al. 2009. Clinical practice recommendations for depression. Acta Psychiatr Scand Suppl 439:8–26.
  • Mann JJ. 2005. The medical management of depression. New Engl J Med 353:1819–1834.
  • Marangell LB. 2000. Augmentation of standard depression therapy. Clin Ther 22(Suppl A):A25–38.
  • Marangell LB. 2001. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry 62(Suppl 18): 12–17.
  • Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. 2008. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28:156–165.
  • Markowitz JC. 2003. Interpersonal psychotherapy for chronic depression. J Clin Psychol 59:847–858.
  • Martin JL, Barbanoj MJ, Schlaepfer TE, Thompson E, Perez V, Kulisevsky J. 2003. Repetitive transcranial magnetic stimulation for the treatment of depression. Systematic review and meta-analysis. Br J Psychiatry 182:480–491.
  • Martiny K, Refsgaard E, Lund V, Lunde M, Sorensen L, Thougaard B, et al. 2012. A 9-week randomized trial comparing a chronotherapeutic intervention (wake and light therapy) to exercise in major depressive disorder patients treated with duloxetine. J Clin Psychiatry 73:1234–1242.
  • Masand PS. 2004. Atypical antipsychotics in the treatment of affective symptoms: a review. Ann Clin Psychiatry 16:3–13.
  • Mathews DC, Henter ID, Zarate CA. 2012. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs 72:1313–1333.
  • Mazeh D, Shahal B, Aviv A, Zemishlani H, Barak Y. 2007. A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. Int Clin Psychopharmacol 22:371–375.
  • McIntyre A, Gendron A, McIntyre A. 2007. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 24:487–494.
  • McIntyre RS, O’Donovan C. 2004. The human cost of not achieving full remission in depression. Can J Psychiatry 49(3 Suppl 1):10–16S.
  • McNamara B, Ray JL, Arthurs OJ, Boniface S. 2001. Transcranial magnetic stimulation for depression and other psychiatric disorders. Psychol Med 31:1141–1146.
  • Mead GE, Morley W, Campbell P, Greig CA, McMurdo M, Lawlor DA. 2008. Exercise for depression. Cochrane Database Syst Rev 4:CD004366.
  • Melander H, Salmonson T, Abadie E, van Zwieten-Boot B. 2008. A regulatory Apologia–a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 18:623–627.
  • Michalets EL. 1998. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84–112.
  • Mintz J, Mintz LI, Arruda MJ, Hwang SS. 1992. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 49:761–768.
  • Miret M, Ayuso-Mateos JL, Sanchez-Moreno J, Vieta E. 2013. Depressive disorders and suicide: epidemiology, risk factors, and burden. Neurosci Biobehav Rev. [Epub ahead of print].
  • Moller HJ. 2003. Suicide, suicidality and suicide prevention in affective disorders. Acta Psychiatr Scand Suppl 418:73–80.
  • Moller HJ. 2006. Is there evidence for negative effects of antidepressants on suicidality in depressive patients?A systematic review. Eur Arch Psychiatry Clin Neurosci 256:476–496.
  • Moller HJ, Baldwin DS, Goodwin G, Kasper S, Okasha A, Stein DJ, et al. 2008. Do SSRIs or antidepressants in general increase suicidality?WPA Section on Pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci 258(Suppl 3):3–23.
  • Moller HJ, Bitter I, Bobes J, Fountoulakis K, Hoschl C, Kasper S. 2012. Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. Eur Psychiatry 27:114–128.
  • Moller HJ, Demyttenaere K, Sacchetti E, Rush AJ, Montgomery SA. 2003. Improving the chance of recovery from the short- and long-term consequences of depression. Int Clin Psychopharmacol 18:219–225.
  • Moncrieff J, Wessely S, Hardy R. 2004. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev 1:CD003012.
  • Montgomery SA. 1991. Selectivity of antidepressants and resistant depression. In: Amsterdam J, editor. Advances in neuropsychiatry and psychopharmacology. New York: Raven Press. p. 93–104.
  • Montgomery SA and Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382–389.
  • Montgomery SA, Kasper S. 2007. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 22: 283–291.
  • Montgomery SA, Moller HJ. 2009. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?Int Clin Psychopharmacol 24:111–118.
  • Mulsant BH, Sweet RA, Rosen J, Pollock BG, Zubenko GS, Flynn T, et al. 2001. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. J Clin Psychiatry 62:597–604.
  • Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. 2013. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197–2223.
  • Mynors-Wallis LM, Gath DH, Day A, Baker F. 2000. Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. Br Med J 320:26–30.
  • Nahas Z, Teneback C, Chae JH, Mu Q, Molnar C, Kozel FA, et al. 2007. Serial vagus nerve stimulation functional MRI in treatment-resistant depression. Neuropsychopharmacology 32:1649–1660.
  • Nakajima S, Uchida H, Suzuki T, Watanabe K, Hirano J, Yagihashi T, et al. 2011. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial. Prog Neuropsychopharmacol Biol Psychiatry 35:1983–1989.
  • Nakhai-Pour HR, Broy P, Berard A. 2010. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 182:1031–1037.
  • National Collaborating Centre for Mental Health (UK). 2010. Depression: The treatment and management of depression in adults (updated edition). Leicester, UK: British Psychological Society. (NICE Clinical Guidelines, No. 90).
  • National Institute for Health & Clinical Excellence. 2009. CG91 Depression with a chronic physical health problem: NICE guideline.
  • Nelson JC. 1998. Treatment of antidepressant nonresponders: augmentation or switch?J Clin Psychiatry 59(Suppl 15): 35–41.
  • Nelson JC. 2003. Managing treatment-resistant major depression. J Clin Psychiatry 64(Suppl 1):5–12.
  • Nelson JC, Delucchi K, Schneider LS. 2008. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry 16:558–567.
  • Nelson JC, Papakostas GI. 2009. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166:980–991.
  • Neumeister A, Goessler R, Lucht M, Kapitany T, Bamas C, Kasper S. 1996. Bright light therapy stabilizes the antidepressant effect of partial sleep deprivation. Biol Psychiatry 39: 16–21.
  • New Zealand Guidelines Group. 2008. Identification of Common Mental Disorders and Management of Depression in Primary Care. An Evidence-based Best Practice Guideline. Wellington: New Zealand Guidelines Group.
  • Nezu AM. 1986. Efficacy of a social problem-solving therapy approach for unipolar depression. J Consult Clin Psychol 54: 196–202.
  • Nierenberg AA, Alpert JE, Gardner-Schuster EE, Seay S, Mischoulon D. 2008. Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression. Biol Psychiatry 64:455–460.
  • Nierenberg AA, Alpert JE, Pava J, Rosenbaum JF, Fava M. 1998. Course and treatment of atypical depression. J Clin Psychiatry 59(Suppl 18):5–9.
  • Nierenberg AA, Amsterdam JD. 1990. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 51(Suppl):39–47.
  • Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, et al. 2000. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 157:1423–1428.
  • Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, et al. 2006. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 163: 1519–1530.
  • Ninan PT, Rush AJ, Crits-Christoph P, Kornstein SG, Manber R, Thase ME, et al. 2002. Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. J Clin Psychiatry 63:434–441.
  • Nobler MS, Sackeim HA. 2000. Electroconvulsive therapy. In: Helmchen H, Henn F, Lauter H, Sartorius N, editors. Contemporary psychiatry. Vol. 3. Berlin: Springer. p. 425–434.
  • Nolen WA, Zohar J, Roose SP, Amsterdam JD. 1994. Refractory depression: current strategies and future directions. Chichester: J. Wiley & Sons.
  • Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, et al. 1997. Neurodevelopment of children exposed in utero to antidepressant drugs. New Engl J Med 336:258–262.
  • Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, et al. 1992. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 86:138–145.
  • Oquendo MA, Baca-Garcia E, Kartachov A, Khait V, Campbell CE, Richards M, et al. 2003. A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. J Clin Psychiatry 64:825–833.
  • Ostad HE, Tadic A, Wagner S, Dragicevic A, Muller MJ, Boland K, et al. 2011. Association between citalopram serum levels and clinical improvement of patients with major depression. J Clin Psychopharmacol 31:281–286.
  • Ostroff RB, Nelson JC. 1999. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 60:256–259.
  • Pagnin D, de Quieroz V, Pini S, Cassano GB. 2004. Efficacy of ECT in depression: a meta-analytic review. J ECT 20:13–20.
  • Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. 2006. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol 26:56–60.
  • Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M. 2004. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry 26:13–17.
  • Pascual-Leone A, Rubio B, Pallardo F, Catala MD. 1996. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 348: 233–237.
  • Paykel ES. 1994. Epidemiology of refractory depression. In: Nolen WA, Zohar J, Roose SP, Amsterdam JD, editors. Refractory depression: current strategies and future directions. Chichester: J. Wiley & Sons, pp. 3–17.
  • Paykel ES, Hollyman JA, Freeling P, Sedgwick P. 1988. Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J Affect Disord 14: 83–95.
  • Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. 1995. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25:1171–1180.
  • Paykel ES, Scott J, Teasdale JD, Johnson AL, Garland A, Moore R, et al. 1999. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry 56:829–835.
  • Pearson KH, Nonacs RM, Viguera AC, Heller VL, Petrillo LF, Brandes M, et al. 2007. Birth outcomes following prenatal exposure to antidepressants. J Clin Psychiatry 68:1284–1289.
  • Peretti S, Judge R, Hindmarch I. 2000. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 403:17–25.
  • Perez M, Pauwels PJ, Pallard-Sigogneau I, Fourrier C, Chopin P, Palmier C, et al. 1998. Design and synthesis of new potent, silent 5-HT1A antagonists by covalent coupling of aminopropanol derivatives with selective serotonin reuptake inhibitors. Bioorg Med Chem Lett 8:3423–3428.
  • Perez-Stable EJ, Miranda J, Munoz RF, Ying YW. 1990. Depression in medical outpatients. Underrecognition and misdiagnosis. Arch Intern Med 150:1083–1088.
  • Perry PJ. 1996. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 39:1–6.
  • Perry PJ, Zeilmann C, Arndt S. 1994. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 14:230–240.
  • Petracca G, Teson A, Chemerinski E, Leiguarda R, Starkstein SE. 1996. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 8:270–275.
  • Petrides G, Fink M, Husain MM, Knapp RG, Rush AJ, Mueller M, et al. 2001. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT 17: 244–253.
  • Picinelli M, Gomez Homen F. 1997. Gender differences in the epidemiology of affective disorders and schizophrenia. Geneva, Switzerland:World Health Organization.
  • Pigott TA, Seay SM. 1999. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 60:101–106.
  • Portella MJ, de Diego-Adelino J, Ballesteros J, Puigdemont D, Oller S, Santos B, et al. 2011. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect?A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry 72:962–969.
  • Posternak MA, Zimmerman M. 2005. Is there a delay in the antidepressant effect?A meta-analysis. J Clin Psychiatry 66: 148–158.
  • Poulet E, Brunelin J, Boeuve C, Lerond J, D’Amato T, Dalery J, et al. 2004. Repetitive transcranial magnetic stimulation does not potentiate antidepressant treatment. Eur Psychiatry 19: 382–383.
  • Preskorn SH. 1993. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 94(5A):2–12S.
  • Preskorn SH, Fast GA. 1991. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 52(Suppl):23–33.
  • Prevention Practice Committee of the American College of Preventive Medicine. 2009. Screening adults for depression in primary care: a position statement of the American College of Preventive Medicine. J Fam Pract 58:535–538.
  • Pridmore S, Turnier-Shea Y. 2004. Medication options in the treatment of treatment-resistant depression. Aust NZ J Psychiatry 38:219–225.
  • Prien RF. 1990. Efficacy of continuation drug therapy of depression and anxiety: issues and methodologies. J Clin Psychopharmacol 10(3 Suppl):86–90S.
  • Prien RF, Kupfer DJ. 1986. Continuation drug therapy for major depressive episodes: how long should it be maintained?Am J Psychiatry 143:18–23.
  • Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, Stephens S, et al. 1996. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 153:985–992.
  • Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA. 2004. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry 55:301–312.
  • Quitkin FM, Harrison W, Stewart JW, McGrath PJ, Tricamo E, Ocepek-Welikson K, et al. 1991. Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design. Arch Gen Psychiatry 48:319–323.
  • Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, McGrath PJ, Harrison W. 1987. Use of pattern analysis to identify true drug response. A replication. Arch Gen Psychiatry 44:259–264.
  • Quitkin FM, Rabkin JG, Ross D, Stewart JW. 1984. Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry 41:782–786.
  • Rabheru K. 2004. Special issues in the management of depression in older patients. Can J Psychiatry 49(3 Suppl 1):41–50S.
  • Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, et al. 2006. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31:2505–2513.
  • Rasmussen BB, Brosen K. 2000. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?Ther Drug Monit 22:143–154.
  • Rasmussen KG, Mueller M, Knapp RG, Husain MM, Rummans TA, Sampson SM, et al. 2007. Antidepressant medication treatment failure does not predict lower remission with ECT for major depressive disorder: a report from the consortium for research in electroconvulsive therapy. J Clin Psychiatry 68:1701–1706.
  • Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X. 2008. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 69:1228–1336.
  • Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. 1993. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services.Arch Gen Psychiatry 50:85–94.
  • Rehm LP. 1979. Behavior therapy for depression. New York: Academic Press.
  • Reynaert-Dupuis C, Zdanowicz N, Leyman S, Mignon A, Seghers S. 2002. for 600A-GAP-BE Study Group: efficacy and tolerance of venlafaxine in depressed patients switched from prior antidepressant treatment. Primary Care Psychiatry 8: 63–68.
  • Reynolds CF III, Frank E, Kupfer DJ, Thase ME, Perel JM, Mazumdar S, et al. 1996. Treatment outcome in recurrent major depression: a post hoc comparison of elderly (“young old”) and midlife patients. Am J Psychiatry 153:1288–1292.
  • Ricken R, Wiethoff K, Reinhold T, Schietsch K, Stamm T, Kiermeir J, et al. 2011. Algorithm-guided treatment of depression reduces treatment costs – results from the randomized controlled German Algorithm Project (GAPII). J Affect Disord 134:249–256.
  • Riise IS, Holm P. 1984. Concomitant isocarboxazid/mianserin treatment of major depressive disorder. J Affect Disord 6: 175–179.
  • Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, et al. 2000. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 157:351–359.
  • Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG, et al. 1998. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. J Am Med Asoc 279:287–291.
  • Roose SP, Sackeim HA, Krishnan KR, Pollock BG, Alexopoulos G, Lavretsky H, et al. 2004. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry 161:2050–2059.
  • Roose SP and Suthers KM. 1998. Antidepressant response in late-life depression. J Clin Psychiatry 59(Suppl 10):4–8.
  • Rosen LN, Targum SD, Terman M, Bryant MJ, Hoffman H, Kasper SF, et al. 1990. Prevalence of seasonal affective disorder at four latitudes. Psychiatry Res 31:131–144.
  • Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. 1998. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 44:77–87.
  • Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y, et al. 1984. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 41:72–80.
  • Rossini D, Lucca A, Zanardi R, Magri L, Smeraldi E. 2005a. Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial. Psychiatry Res 137:1–10.
  • Rossini D, Magri L, Lucca A, Giordani S, Smeraldi E, Zanardi R. 2005b. Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder?A double-blind, randomized, sham-controlled trial. J Clin Psychiatry 66:1569–1575.
  • Rothschild AJ. 2003. Challenges in the treatment of depression with psychotic features. Biol Psychiatry 53:680–690.
  • Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. 1993. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 54:338–342.
  • Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression. 2004. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust NZ J Psychiatry 38:389–407.
  • Rudolph RL, Entsuah R, Chitra R. 1998. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol 18:136–144.
  • Ruhe HG, Booij J, Weert HC, Reitsma JB, Franssen EJ, Michel MC, et al. 2009. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology 34:999–1010.
  • Ruhe HG, van RG, Spijker J, Peeters FP, Schene AH. 2012. Staging methods for treatment resistant depression. A systematic review. J Affect Disord 137–3:35–45.
  • Rumi DO, Gattaz WF, Rigonatti SP, Rosa MA, Fregni F, Rosa MO, et al. 2005. Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study. Biol Psychiatry 57: 162–166.
  • Rush AJ, Kupfer DJ. 2001. Strategies and tactics in the treatment of depression. In: Gabbard GO, editor. Treatment of psychiatric disorders. Washington, DC: American Psychiatric Publishing. p. 1417–1439.
  • Rush AJ, Thase ME. 1999. Psychotherapies for depressive disorders. In: Maj M, Sartorius N, editors. Evidence and Experience in Psychiatry. Volume 1. Depressive disorders. WPA Series. Chichester, UK: John Wiley & Sons, Ltd. p. 161–206.
  • Rush AJ. 1999. Strategies and tactics in the management of maintenance treatment for depressed patients. J Clin Psychiatry 60(Suppl 14):21–26.
  • Rush AJ, BECK AT, Kovacs M, Hollon SD. 1977. Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients. Cognit Ther Res 1:17–37.
  • Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, et al. 2004. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25:119–142.
  • Rush AJ, Koran LM, Keller MB, Markowitz JC, Harrison WM, Miceli RJ, et al. 1998. The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. J Clin Psychiatry 59:589–597.
  • Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, et al. 2011. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 168:689–701.
  • Sackeim HA, Brannan SK, Rush AJ, George MS, Marangell LB, Allen J. 2007. Durability of antidepressant response to vagus nerve stimulation (VNS). Int J Neuropsychopharmacol 10: 817–826.
  • Sackeim HA, Decina P, Portnoy S, Neeley P, Malitz S. 1987. Studies of dosage, seizure threshold, and seizure duration in ECT. Biol Psychiatry 22:249–268.
  • Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, et al. 2001. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. J Am Med Asoc 285:1299–1307.
  • Sackeim HA, Prudic J, Devanand DP, Decina P, Kerr B, Malitz S. 1990. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol 10:96–104.
  • Sackeim HA, Prudic J, Devanand DP, Kiersky JE, Fitzsimons L, Moody BJ, et al. 1993. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. New Engl J Med 328:839–846.
  • Sackeim HA, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S, et al. 2000. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry 57:425–434.
  • Sackeim HA, Roose SP, Burt T. 2005. Optimal length of antidepressant trials in late-life depression. J Clin Psychopharmacol 25(4 Suppl 1):34–S37.
  • Sands BF, Ciraulo DA. 1992. Cocaine drug-drug interactions. J Clin Psychopharmacol 12:49–55.
  • Sartorius N, Baghai TC, Baldwin DS, Barrett B, Brand U, Fleischhacker W, et al. 2007. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol 10(Suppl 1):S1–207.
  • Schatzberg AF. 2000. New indications for antidepressants. J Clin Psychiatry 61(Suppl 11):9–17.
  • Schlaepfer TE, Frick C, Zobel A, Maier W, Heuser I, Bajbouj M, et al. 2008. Vagus nerve stimulation for depression: efficacy and safety in a European study. Psychol Med 38:651–661.
  • Schneier FR, Blanco C, Campeas R, Lewis-Fernandez R, Lin SH, Marshall R, et al. 2003. Citalopram treatment of social anxiety disorder with comorbid major depression. Depress Anxiety 17:191–196.
  • Schuckit MA. 1994. Alcohol and depression: a clinical perspective. Acta Psychiatr Scand Suppl 377:28–32.
  • Schulberg HC, Block MR, Madonia MJ, Scott CP, Rodriguez E, Imber SD, et al. 1996. Treating major depression in primary care practice. Eight-month clinical outcomes. Arch Gen Psychiatry 53:913–919.
  • Schule C, Zwanzger P, Baghai T, Mikhaiel P, Thoma H, Moller HJ, et al. 2003. Effects of antidepressant pharmacotherapy after repetitive transcranial magnetic stimulation in major depression: an open follow-up study. J Psychiatr Res 37:145–153.
  • Scott J. 1988. Chronic depression. Br J Psychiatry 153:287–297.
  • Scott J. 2000. Treatment of chronic depression. New Engl J Med 342:1518–1520.
  • Scott J, Gilvarry E, Farrell M. 1998. Managing anxiety and depression in alcohol and drug dependence. Addict Behav 23:919–931.
  • Seemuller F, Riedel M, Obermeier M, Bauer M, Adli M, Mundt C, et al. 2009. The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. Int J Neuropsychopharmacol 12:181–189.
  • Segal ZV, Kennedy SH, Cohen NL. 2001. Clinical guidelines for the treatment of depressive disorders. V. Combining psychotherapy and pharmacotherapy. Can J Psychiatry 46(Suppl 1): 59–62S.
  • Sharp DJ, Chew-Graham C, Tylee A, Lewis G, Howard L, Anderson I, et al. 2010. A pragmatic randomised controlled trial to compare antidepressants with a community-based psychosocial intervention for the treatment of women with postnatal depression: the RESPOND trial. Health Technol Assess 14:iii–xi, 1.
  • Shelton RC. 2003. The use of antidepressants in novel combination therapies. J Clin Psychiatry 64(Suppl 2):14–18.
  • Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. 2001. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158:131–134.
  • Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, et al. 2005. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 66:1289–1297.
  • Shores MM, Pascualy M, Veith RC. 1998. Major depression and heart disease: treatment trials. Semin Clin Neuropsychiatry 3:87–101.
  • SIGN. 2010. Scottish Intercollegiate Guidelines Network: Non-pharmaceutical management of depression. Available from: http://www.sign.ac.uk/pdf/sign114.pdf [last accessed 11 June 2013].
  • Simon GE, Cunningham ML, Davis RL. 2002. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 159: 2055–2061.
  • Simon GE, Savarino J, Operskalski B, Wang PS. 2006. Suicide risk during antidepressant treatment. Am J Psychiatry 163: 41–47.
  • Souery D, Amsterdam J, de MC, Lecrubier Y, Montgomery S, Lipp O, et al. 1999. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 9–2:83–91.
  • Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, et al. 2011. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. World J Biol Psychiatry 12: 364–375.
  • Soyka M, Lieb M. 2004. Komorbidität von Depression und Alkoholabhängigkeit – Klinische und neurobiologische Aspekte. Nervenheilkunde 1:12–23.
  • Sperling W, Reulbach U, Kornhuber J. 2009. Clinical benefits and cost effectiveness of vagus nerve stimulation in a long-term treatment of patients with major depression. Pharmacopsychiatry 42:85–88.
  • Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF, et al. 1985. The pharmacological treatment of delusional depression. Am J Psychiatry 142:430–436.
  • Spitzer RL, Kroenke K, Williams JB. 1999. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. J Am Med Asoc 282:1737–1744.
  • Stamm TJ, Adli M, Kirchheiner J, Smolka MN, Kaiser R, Tremblay PB, et al. 2008. Serotonin transporter gene and response to lithium augmentation in depression. Psychiatr Genet 18:92–97.
  • Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A. 2007. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 68:1195–1205.
  • Steffens DC, Skoog I, Norton MC, Hart AD, Tschanz JT, Plassman BL, et al. 2000. Prevalence of depression and its treatment in an elderly population: the Cache County study. Arch Gen Psychiatry 57:601–607.
  • Steimer W, Muller B, Leucht S, Kissling W. 2001. Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta 308:33–41.
  • Sternbach H. 1991. The serotonin syndrome. Am J Psychiatry 148:705–713.
  • Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. 2009. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. Br Med J 339:b2880.
  • Storosum JG, Elferink AJ, van Zwieten BJ, van den Brink W, Gersons BP, van SR, et al. 2001. Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur Neuropsychopharmacol 11:173–180.
  • Stowe ZN, Cohen LS, Hostetter A, Ritchie JC, Owens MJ, Nemeroff CB. 2000. Paroxetine in human breast milk and nursing infants. Am J Psychiatry 157:185–189.
  • Sunderland T, Cohen RM, Molchan S, Lawlor BA, Mellow AM, Newhouse PA, et al. 1994. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 51:607–615.
  • Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. 2009. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 70:344–353.
  • Szegedi A, Muller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O. 2003. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 64:413–420.
  • Tadic A, Gorbulev S, Dahmen N, Hiemke C, Braus DF, Roschke J, et al. 2010a. Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder – the EMC trial. Trials 11:21.
  • Tadic A, Helmreich I, Mergl R, Hautzinger M, Kohnen R, Henkel V, et al. 2010b. Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J Affect Disord 120:86–93.
  • Tanaka E, Hisawa S. 1999. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J Clin Pharm Ther 24:7–16.
  • Taragano FE, Lyketsos CG, Mangone CA, Allegri RF, Comesana-Diaz E. 1997. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 38:246–252.
  • Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. 2006. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 63:1217–1223.
  • Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI. 2011. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry 72:1660–1668.
  • Teri L, Reifler BV, Veith RC, Barnes R, White E, McLean P, et al. 1991. Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition. J Gerontol 46:372–377.
  • Thase ME. 1999. Redefining antidepressant efficacy toward long-term recovery. J Clin Psychiatry 60(Suppl 6):15–19.
  • Thase ME. 2001. The clinical, psychosocial, and pharmacoeconomic ramifications of remission. Am J Manag Care 7(11 Suppl): S377–385.
  • Thase ME. 2002. What role do atypical antipsychotic drugs have in treatment-resistant depression?J Clin Psychiatry 63: 95–103.
  • Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, et al. 2007. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 68:224–236.
  • Thase ME, Howland RH, Friedman ES. 1998. Treating antidepressant nonresponders with augmentation strategies: an overview. J Clin Psychiatry 59(Suppl 5):5–12.
  • Thase ME, Rush AJ. 1995. Treatment-resistant depression. In: Bloom FE and Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press. p. 1081–1097.
  • Thase ME, Rush AJ. 1997. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58(Suppl 13):23–29.
  • Thase ME, Shelton RC, Khan A. 2006. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol 26:250–258.
  • Thase ME, Trivedi MH, Rush AJ. 1995. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 12:185–219.
  • Tignol J, Stoker MJ, Dunbar GC. 1992. Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 7:91–94.
  • Tranter R, O’Donovan C, Chandarana P, Kennedy S. 2002. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 27:241–247.
  • Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. 2006. Medication augmentation after the failure of SSRIs for depression. New Engl J Med 354:1243–1252.
  • Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, et al. 2004. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 61:669–680.
  • Tuccori M, Testi A, Antonioli L, Fornai M, Montagnani S, Ghisu N, et al. 2009. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther 31(Pt 1):1426–1453.
  • Tuunainen A, Kripke DF, Endo T. 2004. Light therapy for non-seasonal depression. Cochrane Database Syst Rev 2:CD004050.
  • Uher R. 2011. Genes, environment, and individual differences in responding to treatment for depression. Harv Rev Psychiatry 19:109–124.
  • Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, et al. 2009. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 9: 225–233.
  • Uher R, Muthen B, Souery D, Mors O, Jaracz J, Placentino A, et al. 2010. Trajectories of change in depression severity during treatment with antidepressants. Psychol Med 40:1367–1377.
  • Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. 2008. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57:203–209.
  • UK ECT Group. 2003. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361(9360):799–808.
  • Unutzer J, Patrick DL, Diehr P, Simon G, Grembowski D, Katon W. 2000. Quality adjusted life years in older adults with depressive symptoms and chronic medical disorders. Int Psychogeriatr 12:15–33.
  • US Preventive Services Task Force. 2009. Screening and treatment for major depressive disorder in children and adolescents: US Preventive Services Task Force Recommendation Statement. Pediatrics 123:1223–1228.
  • Üstün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. 2004. Global burden of depressive disorders in the year 2000. Br J Psychiatry 184:386–392.
  • Üstün TB, Sartorius N. 1995. Mental Illness in general health care: an international study. Chichester: Wiley.
  • Van den Hoofdakker RH. 1994. Chronobiological theories of nonseasonal affective disorders and their implications for treatment. J Biol Rhythms 9:157–183.
  • Versiani M, Oggero U, Alterwain P, Capponi R, Dajas F, Heinze-Martin G, et al. 1989. A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes. Br J Psychiatry Suppl 6:72–77.
  • Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. 2013. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2163–2196.
  • Wang J. 2004. A longitudinal population-based study of treated and untreated major depression. Med Care 42:543–550.
  • Waraich P, Goldner EM, Somers JM, Hsu L. 2004. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry 49:124–138.
  • Wasserman D, Rihmer Z, Rujescu D, Sarchiapone M, Sokolowski M, Titelman D, et al. 2012. The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. Eur Psychiatry 27:129–141.
  • Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, et al. 2011. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev 12:CD006528.
  • Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, et al. 2008. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. J Clin Psychiatry 69:1404–1415.
  • Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. 1989. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. J Am Med Asoc 262:914–919.
  • Werneke U, Horn O, Taylor DM. 2004. How effective is St John's wort?The evidence revisited. J Clin Psychiatry 65:611–617.
  • Werneke U, Northey S, Bhugra D. 2006. Antidepressants and sexual dysfunction. Acta Psychiatr Scand 114:384–397.
  • WHO. 1992. The ICD-10 Classification of Mental and Behavioural Disorders – Clinical Descriptions and Diagnostic Guidelines. Geneva:World Health Organization.
  • WHO. 2004. World Health Organization The global burden of disease: 2004 update. Geneva:World Health Organization.
  • Whyte EM, Dew MA, Gildengers A, Lenze EJ, Bharucha A, Mulsant BH, et al. 2004. Time course of response to antidepressants in late-life major depression: therapeutic implications. Drugs Aging 21:531–554.
  • Wiegand MH, Lauer CJ, Schreiber W. 2001. Patterns of response to repeated total sleep deprivations in depression. J Affect Disord 64:257–260.
  • Wijkstra J, Burger H, van den Broek WW, Birkenhager TK, Janzing JG, Boks MP, et al. 2010. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr Scand 121:190–200.
  • Wijkstra J, Lijmer J, Balk FJ, Geddes JR, Nolen WA. 2006. Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Br J Psychiatry 188: 410–415.
  • Wirz-Justice A, Graw P, Krauchi K, Sarrafzadeh A, English J, Arendt J, et al. 1996. ‘Natural’ light treatment of seasonal affective disorder. J Affect Disord 37:109–120.
  • Wirz-Justice A, Van den Hoofdakker RH. 1999. Sleep deprivation in depression: what do we know, where do we go?Biol Psychiatry 46:445–453.
  • Wisner KL, Perel JM, Findling RL. 1996. Antidepressant treatment during breast-feeding. Am J Psychiatry 153:1132–1137.
  • Wittchen HU. 2000. Epidemiology of affective disorders. In: Helmchen H, Henn F, Lauter H, Sartorius N. Contemporary psychiatry. Vol 3. Heidelberg: Springer. p. 231–241.
  • Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. 2011. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655–679.
  • Wittchen HU, Lieb R, Wunderlich U, Schuster P. 1999. Comorbidity in primary care: presentation and consequences. J Clin Psychiatry 60(Suppl 7):29–36.
  • Woodgett JR. 1990. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9:2431–2438.
  • Working Group on the Management of Major Depression in Adults. 2008. Clinical practice guideline on the management of major depression in adults. Madrid: Ministry of Health and Consumer Affairs, Galician Health Technology Assessment Agency (HTA) (avalia-t).
  • Worthington JJ, Peters PM. 2003. Treatment of antidepressant-induced sexual dysfunction. Drugs Today (Barc.) 39:887–896.
  • Wu JC, Bunney WE. 1990. The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry 147:14–21.
  • Wulsin LR, Vaillant GE, Wells VE. 1999. A systematic review of the mortality of depression. Psychosom Med 61:6–17.
  • Yin L, Wang J, Klein PS, Lazar MA. 2006. Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock. Science 311:1002–1005.
  • Zajecka J. 2001. Strategies for the treatment of antidepressant-related sexual dysfunction. J Clin Psychiatry 62(Suppl 3):35–43.
  • Zesiewicz TA, Gold M, Chari G, Hauser RA. 1999. Current issues in depression in Parkinson's disease. Am J Geriatr Psychiatry 7:110–118.
  • Zullino D, Baumann P. 2001. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 34:119–127.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.